title: Beneficial effect of post-procedural abciximab in patients undergoing primary coronary angioplasty and presenting with the no-reflow phenomenon.
abstract: We sought to investigate the effect of post-procedural abciximab on clinical outcome of patients presenting the no-reflow phenomenon after primary angioplasty. We retrospectively selected 38 patients who developed the no-reflow phenomenon after primary angioplasty: 18 received post-procedural abciximab, 20 age- and sex-matched patients who did not receive abciximab were considered as concurrent controls. At 6 months follow-up, the clinical course was uneventful in the abciximab group while the composite end-point of major adverse cardiac events occurred in 8 patients (40%) in the control group (P=0.009). 'Rescue' administration of abciximab is an effective option for the treatment of the no-reflow phenomenon determining significant prognostic improvements.
authors.affiliation: Department of Cardiology, University of Siena, Siena, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Picchi
authors.forename: Valerio
authors.initials: V
authors.lastname: Zaca
authors.forename: Marta
authors.initials: M
authors.lastname: Focardi
authors.forename: Massimo
authors.initials: M
authors.lastname: Fineschi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Sinicropi
authors.forename: Stefano
authors.initials: S
authors.lastname: Casini
authors.forename: Alberto
authors.initials: A
authors.lastname: Buti
authors.forename: Carlo
authors.initials: C
authors.lastname: Pierli
authors.forename: Sergio
authors.initials: S
authors.lastname: Mondillo
authors.forename: Mario
authors.initials: M
authors.lastname: Marzilli
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D017023:Coronary Angiography; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab